Clostridium Difficile Infection: Clinical Trials

23 trials for Clostridium Difficile Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 6 terminated, 3 unknown, 1 recruiting. 23 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 323Completed 13, Terminated 6, Unknown 3, Recruiting 1
Phase 25Terminated 3, Recruiting 1, Unknown 1

Follow Clostridium Difficile Infection: new trials by email Literature Review of Clostridium Difficile Infection trials Research Report on Clostridium Difficile Infection

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
Vancomycin 125mg, Placebo - Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection
Phase 2 / Phase 3RecruitingRiverside University Health System Medical Center1762024-10-212025-11-10
Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection
Fecal filtrate transplantation, Conventional fecal microbiota transplantation - Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection
Phase 3UnknownUniversity of Pecs2382023-11-012023-05-19
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection
Vancomycin, Placebos - Clostridium Difficile Infection
Phase 3CompletedMcGill University Health Centre/Research Institute of the McGill University Health Centre2632020-11-192025-12-10
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)
RBX2660 - Clostridium Difficile Infection, Infection
Phase 3CompletedRebiotix Inc.7932019-07-302024-08-07
Fecal Transplantation for Primary Clostridium Difficile Infection
Fecal microbiota transplantation, Vancomycin - Clostridium Difficile Infection
Phase 3TerminatedOslo University Hospital1042019-07-172024-09-19
Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)
Fecal Microbiota Therapy (FMT), Placebo - Clostridium Difficile Infection
Phase 2 / Phase 3TerminatedVA Office of Research and Development1532018-11-152024-04-11
Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD) - Clostridium Difficile Infection
Phase 3CompletedMerck Sharp & Dohme LLC1482018-03-272023-07-27
ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
SER-109, Placebo - Clostridium Difficile Infection
Phase 3CompletedSeres Therapeutics, Inc.1822017-07-102023-04-27
Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)
Cadazolid, Vancomycin capsule, Vancomycin solution - Clostridium Difficile Infection
Phase 2 / Phase 3TerminatedActelion12017-04-142025-07-08
Clostridium Difficile Vaccine Efficacy Trial
Clostridium difficile vaccine, Placebo - Clostridium Difficile Infection
Phase 3CompletedPfizer175352017-03-292023-02-13
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection
Fecal Microbiota, vancomycin, Loperamide - Clostridium Difficile Infection
Phase 2 / Phase 3UnknownQueen Elizabeth II Health Sciences Centre502016-12-012016-09-27
Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection
Fecal microbiota transplantation, Fidaxomicin, Vancomycin - Clostridium Difficile Infection
Phase 3CompletedUniversity of Aarhus642016-04-012019-10-15
Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection
Fidaxomicin - Clostridium Difficile Infection
Phase 3TerminatedMcMaster University312015-07-012023-03-24
IMT for Primary Clostridium Difficile Infection
Intestinal microbiota therapy, Metronidazole - Clostridium Difficile Infection
Phase 2 / Phase 3TerminatedOslo University Hospital212015-02-222020-09-22
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea
Cadazolid, Vancomycin, Cadazolid-matching placebo - Clostridium Difficile Infection
Phase 3CompletedActelion6322014-03-272025-02-04
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea
Cadazolid, Vancomycin, Cadazolid-matching placebo - Clostridium Difficile Infection
Phase 3CompletedActelion6312013-12-122025-02-04
Transplantation of Fecal Microbiota for Clostridium Difficile Infection
Fecal Microbiota transplantation. - Clostridium Difficile Infection
Phase 3UnknownTel-Aviv Sourasky Medical Center102013-11-012013-10-09
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline - Clostridium Difficile Infection
Phase 3TerminatedSanofi Pasteur, a Sanofi Company93022013-07-302022-03-28
Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
Surotomycin, Vancomycin, Placebo - Clostridium Difficile Infection
Phase 3CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6062012-05-162019-07-23
A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)
CB-183,315, Vancomycin, Placebo - Clostridium Difficile Infection
Phase 3CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6082012-05-162022-08-22

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Clostridium Infections (23)  ·  Diarrhea (6)  ·  Communicable Diseases (2)  ·  Infections (2)  ·  Enterocolitis, Pseudomembranous (1)  ·  Gastroenteritis (1)  ·  Recurrence (1)  ·  Reinfection (1)

Broader conditions

Bacterial Infections (23)  ·  Bacterial Infections and Mycoses (23)  ·  Gram-Positive Bacterial Infections (23)  ·  Infections (21)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Signs and Symptoms (6)  ·  Signs and Symptoms, Digestive (6)  ·  Disease Attributes (4)  ·  Pathologic Processes (4)  ·  Digestive System Diseases (2)  ·  Gastrointestinal Diseases (2)  ·  Enterocolitis (1)  ·  Gastroenteritis (1)  ·  Intestinal Diseases (1)  ·  Recurrence (1)

Interventions

Vancomycin (10)  ·  Fecal Microbiota Transplantation (4)  ·  bezlotoxumab (3)  ·  cadazolid (3)  ·  CB-183,315 (2)  ·  Fidaxomicin (2)  ·  Metronidazole (2)  ·  Loperamide (1)  ·  Saline Solution (1)  ·  actoxumab (1)

Sponsors

Actelion (3)  ·  Merck Sharp & Dohme LLC (3)  ·  Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2)  ·  Oslo University Hospital (2)  ·  McGill University Health Centre/Research Institute of the McGill University Health Centre (1)  ·  McMaster University (1)  ·  Pfizer (1)  ·  Queen Elizabeth II Health Sciences Centre (1)  ·  Rebiotix Inc. (1)  ·  Riverside University Health System Medical Center (1)  ·  Sanofi Pasteur, a Sanofi Company (1)  ·  Seres Therapeutics, Inc. (1)  ·  St Marina University Hospital, Varna, Bulgaria (1)  ·  Tel-Aviv Sourasky Medical Center (1)  ·  University of Aarhus (1)

Countries

United States (8)  ·  Canada (7)  ·  Hungary (4)  ·  Poland (4)  ·  Spain (4)  ·  Colombia (3)  ·  Czechia (3)  ·  Germany (3)  ·  Norway (3)  ·  Sweden (3)  ·  United Kingdom (3)  ·  Argentina (2)  ·  Australia (2)  ·  Belgium (2)  ·  Brazil (2)

Top investigators

Anne Claire Marrast, MD (2)  ·  Aasma Shaukat, MD MPH (1)  ·  Christine H Lee, MD (1)  ·  Dimitri M Drekonja, MD (1)  ·  Emily G McDonald, MD MSc (1)  ·  Ian R Davis, MD,FRCPC (1)  ·  Jens F Dahlerup, MD DrMSc (1)  ·  Kjetil K Garborg, MD, Ph.d. (1)  ·  Lisa von Moltke, MD (1)  ·  Michael Bretthauer, MD, PhD (1)  ·  Michael Bretthauer, Ph.d. (1)  ·  Miglena I Georgieva, PhD (1)  ·  Teena Chopra, M.D., M.P.H. (1)

Results publications

PMID 28121498, PMID 29538686, PMID 29680101, PMID 29788418, PMID 30060024, PMID 30227108, PMID 30455246, PMID 30460321, PMID 30709665, PMID 31411386, PMID 31628838, PMID 32099847, PMID 32376702, PMID 32504314, PMID 32747931, PMID 36661328, PMID 24762631, PMID 27316794, PMID 28480267, PMID 28961905, PMID 30610862, PMID 31846705, PMID 31883370, PMID 32101275, PMID 32946836, PMID 33106983, PMID 34150673, PMID 34154439, PMID 35045228, PMID 35463939, PMID 36716031, PMID 36906440, PMID 37389891, PMID 38941068, PMID 39180325, PMID 39180326, PMID 39271107, PMID 40177588, PMID 40523286, PMID 40784972, PMID 41245385, PMID 41491103, PMID 41653256, PMID 41758514, PMID 42286373, PMID 42840322

NIH funding

2015 (1), 2016 (1), 2017 (1)